South Korea Chorea Market

ID: MRFR/HC/51939-HCR 200 Pages Vikita Thakur Last Updated: September 17, 2026
South Korea Chorea Market Research Report By Distribution Channel (hospitals, clinics, diagnostic centers, drug stores, pharmacies, others), By Symptoms (involuntary muscle movements, milkmaid's grip, speech problems, seizures), By End User (clinics, hospitals, ambulatory surgical centers, others), By Product Type (Medication, Surgery therapy) and By Treatment (Medical care, Surgical care) -Forecast to 2035
South Korea Chorea Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)6.37%
2024 Market Size$ 20 Million
2025 Market Size$ 21.27 Million
2035 Market Size$ 39.43 Million
Key Players
Teva Pharmaceutical Industries Ltd
Bristol-Myers Squibb Company
AbbVie Inc
Novartis AG
Roche Holding AG
Sanofi
Trends
  • Rising Awareness and Diagnosis
  • Innovative Treatment Options
  • Government Support for Research
Opportunities
  • Increasing Prevalence of Chorea
  • Enhanced Patient Support Services
  • Advancements in Diagnostic Technologies
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Medical Device, BY Type (USD Million)
      1. 4.1.1 Huntington's disease
      2. 4.1.2 Rheumatic (Sydenham's Chorea)
      3. 4.1.3 Drug-induced Chorea
    2. 4.2 Medical Device, BY Treatment (USD Million)
      1. 4.2.1 Medical care
      2. 4.2.2 Surgical care
    3. 4.3 Medical Device, BY Distribution Channel (USD Million)
      1. 4.3.1 Hospitals
      2. 4.3.2 Clinics
      3. 4.3.3 Diagnostic centers
      4. 4.3.4 Drug stores
      5. 4.3.5 Pharmacies
      6. 4.3.6 Others
    4. 4.4 Medical Device, BY Symptoms (USD Million)
      1. 4.4.1 Involuntary muscle movements
      2. 4.4.2 Milkmaid's grip
      3. 4.4.3 Speech problems
      4. 4.4.4 Seizures
    5. 4.5 Medical Device, BY End-Users (USD Million)
      1. 4.5.1 Clinics
      2. 4.5.2 Hospitals
      3. 4.5.3 Ambulatory surgical centers
      4. 4.5.4 Others
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Medical Device
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Medical Device
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Teva Pharmaceutical Industries Ltd (IL)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Bristol-Myers Squibb Company (US)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 AbbVie Inc (US)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Novartis AG (CH)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Roche Holding AG (CH)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Sanofi (FR)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 Pfizer Inc (US)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Eli Lilly and Company (US)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
      9. 5.2.9 AstraZeneca PLC (GB)
        1. 5.2.9.1 Financial Overview
        2. 5.2.9.2 Products Offered
        3. 5.2.9.3 Key Developments
        4. 5.2.9.4 SWOT Analysis
        5. 5.2.9.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 SOUTH KOREA MARKET ANALYSIS BY TYPE
    3. 6.3 SOUTH KOREA MARKET ANALYSIS BY TREATMENT
    4. 6.4 SOUTH KOREA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    5. 6.5 SOUTH KOREA MARKET ANALYSIS BY SYMPTOMS
    6. 6.6 SOUTH KOREA MARKET ANALYSIS BY END-USERS
    7. 6.7 KEY BUYING CRITERIA OF MEDICAL DEVICE
    8. 6.8 RESEARCH PROCESS OF MRFR
    9. 6.9 DRO ANALYSIS OF MEDICAL DEVICE
    10. 6.10 DRIVERS IMPACT ANALYSIS: MEDICAL DEVICE
    11. 6.11 RESTRAINTS IMPACT ANALYSIS: MEDICAL DEVICE
    12. 6.12 SUPPLY / VALUE CHAIN: MEDICAL DEVICE
    13. 6.13 MEDICAL DEVICE, BY TYPE, 2024 (% SHARE)
    14. 6.14 MEDICAL DEVICE, BY TYPE, 2024 TO 2035 (USD Million)
    15. 6.15 MEDICAL DEVICE, BY TREATMENT, 2024 (% SHARE)
    16. 6.16 MEDICAL DEVICE, BY TREATMENT, 2024 TO 2035 (USD Million)
    17. 6.17 MEDICAL DEVICE, BY DISTRIBUTION CHANNEL, 2024 (% SHARE)
    18. 6.18 MEDICAL DEVICE, BY DISTRIBUTION CHANNEL, 2024 TO 2035 (USD Million)
    19. 6.19 MEDICAL DEVICE, BY SYMPTOMS, 2024 (% SHARE)
    20. 6.20 MEDICAL DEVICE, BY SYMPTOMS, 2024 TO 2035 (USD Million)
    21. 6.21 MEDICAL DEVICE, BY END-USERS, 2024 (% SHARE)
    22. 6.22 MEDICAL DEVICE, BY END-USERS, 2024 TO 2035 (USD Million)
    23. 6.23 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 South Korea MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY TYPE, 2025-2035 (USD Million)
      2. 7.2.2 BY TREATMENT, 2025-2035 (USD Million)
      3. 7.2.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Million)
      4. 7.2.4 BY SYMPTOMS, 2025-2035 (USD Million)
      5. 7.2.5 BY END-USERS, 2025-2035 (USD Million)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

South Korea South Korea Chorea Market Segmentation

South Korea Chorea Market By Type (USD Million, 2025-2035)

  • Huntington's disease
  • Rheumatic (Sydenham's Chorea)
  • Drug-induced Chorea

South Korea Chorea Market By Treatment (USD Million, 2025-2035)

  • Medical care
  • Surgical care

South Korea Chorea Market By Distribution Channel (USD Million, 2025-2035)

  • Hospitals
  • Clinics
  • Diagnostic centers
  • Drug stores
  • Pharmacies
  • Others

South Korea Chorea Market By Symptoms (USD Million, 2025-2035)

  • Involuntary muscle movements
  • Milkmaid's grip
  • Speech problems
  • Seizures

South Korea Chorea Market By End-Users (USD Million, 2025-2035)

  • Clinics
  • Hospitals
  • Ambulatory surgical centers
  • Others

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories

Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.